Cited by 781AI in cancer detectionArtificial Intelligence in Healthcare and EducationRadiomics and Machine Learning in Medical Imaging

Artificial Intelligence in Cancer Research and Precision Medicine

Open access
Bhinder, Bhavneet, Gilvary, Coryandar, Madhukar, Neel S., Elemento, Olivier·2021·Cancer Discovery

Abstract

Artificial intelligence (AI) is rapidly reshaping cancer research and personalized clinical care. Availability of high-dimensionality datasets coupled with advances in high-performance computing, as well as innovative deep learning architectures, has led to an explosion of AI use in various aspects of oncology research. These applications range from detection and classification of cancer, to molecular characterization of tumors and their microenvironment, to drug discovery and repurposing, to predicting treatment outcomes for patients. As these advances start penetrating the clinic, we foresee a shifting paradigm in cancer care becoming strongly driven by AI. SIGNIFICANCE: AI has the potential to dramatically affect nearly all aspects of oncology-from enhancing diagnosis to personalizing treatment and discovering novel anticancer drugs. Here, we review the recent enormous progress in the application of AI to oncology, highlight limitations and pitfalls, and chart a path for adoption of AI in the cancer clinic.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-21-0090

Cites

120 of 120 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Liquid biopsies allow comprehensive cancer profile evaluation non-invasively and in real-time.

    “Liquid biopsies allow a comprehensive cancer profile to be evaluated in a non-invasive and real-time manner and help discover more data for cancer research, including CTCs, cfDNA, exosomes, etc.”

    From Artificial intelligence in pancreatic cancer (2022) · cites this paper as [171]

    In “On the Road to Early Cancer Detection” (page not provided), the paper describes liquid biopsies as minimally invasive blood tests that can, in theory, aid early detection and monitoring over time. It does not say they provide a comprehensive cancer profile in real time; the passage discusses ctDNA and cfDNA, not the sentence’s examples of CTCs and exosomes. (LLM, conf=0.86)

    Experimental — accuracy not yet measured
  • AI can analyze biomarkers from liquid biopsies for association with diseases.

    “The biomarkers in these data can be analyzed using AI for their association with diseases.”

    From Artificial intelligence in pancreatic cancer (2022) · cites this paper as [171]

  • Modern clinical oncology faces data complexity that exceeds human analytical capacity.

    “Modern clinical oncology faces an unprecedented data complexity that exceeds human analytical capacity”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 8

  1. [8]Al-Haija QA, Adebanjo A. Breast Cancer Diagnosis in Histopathological Images Using ResNet-50 Convolutional Neural Network. IEEE International IOT, IEMTRONICS 2020: 1– 7.
  2. [44]Jain MS, Massoud TF. Predicting tumour mutational burden from histopathological images using multiscale deep learning. Nat Mach Intell 2020; 2: 356– 62.
  3. [45]Wang L, Jiao Y, Qiao Y, Zeng N, Yu R. A novel approach combined transfer learning and deep learning to predict TMB from histology image. Pattern Recognit. Lett 2020; 135: 244– 48.
  4. [47]Xu Z, Verma A, Naveed U, Bakhoum S, Khosravi P, Elemento O. Using Histopathology Images to Predict Chromosomal Instability in Breast Cancer: A Deep Learning Approach. medRxiv 2020.09.23.20200139. 10.1101/2020.09.23.20200139. · DOI
  5. [65]Tran NH, Qiao R, Xin L, Chen X, Shan B, Li M. Personalized deep learning of individual immunopeptidomes to identify neoantigens for cancer vaccines. Nat Mach Intell 2020; 2: 764– 71.
  6. [69]Klein TE, Chang JT, Cho MK, Easton KL, Fergerson R, Hewett M, Integrating genotype and phenotype information: an overview of the PharmGKB project. Pharmacogenetics Research Network and Knowledge Base. Pharmacogenomics J 2001; 1: 167– 70. 11908751
  7. [102]Lou B, Doken S, Zhuang T, Wingerter D, Gidwani M, Mistry N, An image-based deep learning framework for individualizing radiotherapy dose. Lancet Digit Health 2019; 1: e136– 47. 31448366 PMC6708276
  8. [121]Gilvary C, Dry JR, Elemento O. Multi-task learning predicts drug combination synergy in cells and in the clinic. bioRxiv 576017; doi: 10.1101/5760. · DOI

Cited by

Sorted by citations

Authors
Bhinder, B., Gilvary, C., Madhukar, N. S., & Elemento, O.
Affiliations
  • Cornell University (US)
  • 3OneThree Biotech, New York, New York.
Corresponding author
Elemento, Olivier
Venue
Cancer Discovery
Published
2021-04-01
Volume
11
Issue
4
Pages
900-915
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W3146345129
Cited by
781
References
120
Citations by year
2026: 130 · 2025: 274 · 2024: 182 · 2023: 129 · 2022: 54 · 2021: 12
FWCI
6.76
Type
journal article
Language
en
Open access
Locations
  • Cancer Discovery (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • NIH (UL1TR002384, R01CA194547)
  • Leukemia and Lymphoma Society Specialized Center of Research (180078-02, 7021-20)
Topics
  • Physical Sciences › Computer Science › Artificial Intelligence › AI in cancer detection
  • Health Sciences › Medicine › Health Informatics › Artificial Intelligence in Healthcare and Education
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiomics and Machine Learning in Medical Imaging
Keywords
artificial intelligence, cancer research, precision medicine, tumor molecular profiling, tumor microenvironment, anticancer drug discovery, drug repurposing, treatment outcome prediction, clinical adoption of AI
MeSH terms
Antineoplastic Agents, Artificial Intelligence, Humans, Medical Oncology, Neoplasms, Research, Precision Medicine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review